ReNeuron Group plc Exosome data presented at ISCT conference (1028N)
May 04 2018 - 2:00AM
UK Regulatory
TIDMRENE
RNS Number : 1028N
ReNeuron Group plc
04 May 2018
AIM: RENE 4 May 2018
ReNeuron Group plc
("ReNeuron" or the "Company")
Exosome data presented at ISCT conference
Positive pre-clinical data in cancer with ReNeuron's ExoPr0
exosome therapy candidate accepted for podium presentation at the
2018 International Society of Cell Therapy (ISCT) annual
meeting
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the
development of cell-based therapeutics, is pleased to announce that
new and positive pre-clinical data relating to its ExoPr0 stem
cell-derived exosome therapy candidate will be presented today at
ISCT 2018, a leading scientific conference taking place this week
in Montreal, Canada.
Exosomes are nanoparticles secreted from many different types of
cells, including the Company's proprietary CTX stem cell line. They
play a key role in cell-to-cell signalling, and early research with
ExoPr0 has demonstrated their potential as both a novel therapeutic
candidate and as a drug delivery vehicle.
Dr Randolph Corteling, Head of Research at ReNeuron, will
present data demonstrating for the first time that the ExoPr0
candidate induces apoptosis (cell death) and/or senescence
(arresting of cell growth) in a number of cancer cell lines. The
podium presentation will also show for the first time that ExoPr0
significantly reduces tumour volume in a variety of in vivo
xenograft models of cancer. These results, albeit early-stage, are
particularly encouraging as they demonstrate the potential of
ExoPr0 as a monotherapy with a comparable efficacy profile to the
standard of care in a relevant cancer model. Further, when combined
with the current standard of care therapy, ExoPr0 induces an
additive reduction of tumour volume, indicating distinct mechanisms
by which ExoPr0 exerts its therapeutic effect as well as its
potential utility as a combination therapy.
ReNeuron continues to build the pre-clinical data package for
its ExoPr0 exosome therapy candidate and has recently commenced
discussions with regulatory authorities regarding the potential
regulatory pathway to the clinic for ExoPr0. Subject to continued
success with ongoing pre-clinical development work, the Company
hopes to be able to commence clinical development with ExoPr0
during 2019.
Further information about this conference may be found at
www.isct2018.com.
Commenting on the data, Dr Randolph Corteling, Head of Research
at ReNeuron, said:
"The data being presented at the ISCT 2018 conference represent
a further advance in the development of our ExoPr0 exosome
therapeutic candidate. We draw considerable encouragement from
these new pre-clinical results and look forward to presenting
further progress with the development of ExoPr0 as a potential new
and highly novel cancer therapy in the months ahead."
Capital markets event:
As previously announced, ReNeuron will be hosting a capital
markets event on the Company's exosome nanomedicine platform on
Thursday 17 May 2018. The event, for analysts and institutional
investors, will take place at 2.30pm at the offices of Buchanan,
107 Cheapside, London EC2V 6DN.
For further details please contact Buchanan on 020 7466
5000.
ENDS
Enquiries:
+44 (0)20 3819
ReNeuron 8400
Olav Hellebø , Chief Executive
Officer
Michael Hunt, Chief Financial Officer
+44 (0) 20 7466
Buchanan 5000
Mark Court, Sophie Wills, Stephanie
Watson
Stifel Nicolaus Europe Limited
Jonathan Senior, Stewart Wallace, Ben +44 (0) 20 7710
Maddison (NOMAD and Joint Broker) 7600
N+1 Singer Advisory LLP +44 (0) 20 7496
Mark Taylor (Joint Broker) 3000
About ReNeuron
ReNeuron is a leading, clinical-stage cell therapy development
company. Based in the UK, its primary objective is the development
of novel cell-based therapies targeting areas of significant unmet
or poorly met medical need.
ReNeuron has used its unique stem cell technologies to develop
cell-based therapies for significant disease conditions where the
cells can be readily administered "off-the-shelf" to any eligible
patient without the need for additional immunosuppressive drug
treatments. The Company has therapeutic candidates in clinical
development for disability as a result of stroke and for the
blindness-causing disease, retinitis pigmentosa.
ReNeuron is also advancing its proprietary exosome technology
platform as a potential new nanomedicine targeting cancer and as a
potential delivery system for drugs that would otherwise be unable
to reach their site of action.
ReNeuron's shares are traded on the London AIM market under the
symbol RENE.L. Further information on ReNeuron and its products can
be found at www.reneuron.com.
This announcement contains forward-looking statements with
respect to the financial condition, results of operations and
business achievements/performance of ReNeuron and certain of the
plans and objectives of management of ReNeuron with respect
thereto. These statements may generally, but not always, be
identified by the use of words such as "should", "expects",
"estimates", "believes" or similar expressions. This announcement
also contains forward-looking statements attributed to certain
third parties relating to their estimates regarding the growth of
markets and demand for products. By their nature, forward-looking
statements involve risk and uncertainty because they reflect
ReNeuron's current expectations and assumptions as to future events
and circumstances that may not prove accurate. A number of factors
could cause ReNeuron's actual financial condition, results of
operations and business achievements/performance to differ
materially from the estimates made or implied in such
forward-looking statements and, accordingly, reliance should not be
placed on such statements.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCEAESDELAPEAF
(END) Dow Jones Newswires
May 04, 2018 02:00 ET (06:00 GMT)
Reneuron (LSE:RENE)
Historical Stock Chart
From Apr 2024 to May 2024
Reneuron (LSE:RENE)
Historical Stock Chart
From May 2023 to May 2024